Akademik Veri Yönetim Sistemi
Klinik Gelisim, cilt.8, sa.11, ss.3920-3924, 1995 (Scopus)
In this study the effect of nicotinamide therapy (NCT) in recent-onset type 1 diabetes patients with different beta cell reserve has been evaluated. Intensive insulin therapy (IIT) for 6 weeks has been administered to 61 type 1 patients within first 2 weeks of diagnosis. Diabetic patients were divided into three groups based on remission status after IIT; complete remission (CR, group I), incomplete remission (ICR, group II) and non-remission (NR, group III). The sex (F/M), mean age (years), basal and glucagon stimulated C-peptide levels (ng/ml) were as follows: In group I; 6/14, 17.1 and 1.08 ± 0.39/1.73 ± 0.61; in group II 7/11, 13.4 and 0.67 ± 0.43/1.01 ± 0.56 and in group III 12/11, 11.8 and 0.28 ± 0.20/0.46 ± 0.19, respectively. Patients in each group were randomly assigned further into two subgroups. First group (A) was given nicotinamide 25 mg/kg/day p.o. for 12 months and second group (B) was given only insulin therapy (if needed to maintain normoglycemia as in group A). Groups A and B were evaluated at 3. 6. 9. and 12. months in terms of remission status and beta cell insulin secretion capacity. In the NCT treated CR group, preservation of complete remission at 6 months was approximately 5 times higher than in non-treated group (group IA 54.5 %, group IB 11.1 %). CR and ICR rations in group IA was still quite higher at 12. month (CR rates: 18.2 % and 0 %; and ICR rates: 63.6 % and 44.4 % in groups IA and IB, respectively). While in groups IIA and IIB and groups IIIA and IIIB, there were no patients in CR at 6. month. On the other hand ICR rates at the same time in groups IIA and IIB were 40 % and 25 %, and groups IIIA and IIIB were 8.3 % and 9.1 %, respectively. In conclusion, our study indicated that NCT seems to be more efficient in those patients with better beta cell reserve, and not effective in patients with unsufficient reserve.